7月22日，Ionis Pharmaceuticals盘中下跌5.16%，报51.395美元/股，成交额3660.52万美元。
消息面上，公司与阿斯利康联合开发的Eplontersen心脏转归III期试验（Cardio-Ttransform）于7月9日公布结果，在第140周未达主要终点，股价此前已单日暴跌超20%。随后RBC将目标价从100美元下调至85美元，TD Cowen从108美元下调至94美元。同时公司将于7月29日发布Q2财报，机构对本季度业绩持偏谨慎态度，核心担忧在于高基数后缺乏同量级合作里程碑，营收与利润率面临回落压力。心血管核心管线受挫、目标价下修及财报不确定性三重因素叠加，短期内持续压制股价。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.